28410205|t|Variant 2 of KIAA0101, antagonizing its oncogenic variant 1, might be a potential therapeutic strategy in hepatocellular carcinoma
28410205|a|Hepatocellular carcinoma (HCC) is one of the most lethal malignant tumors worldwide and effective therapies, including molecular therapy, remain elusive. Our previous work demonstrates that oncogenic KIAA0101 transcript variant (tv) 1 promotes HCC development and might be a HCC therapeutic target. However, the function of another KIAA0101 variant, KIAA0101 tv2, remains unknown. In this study, we reported that KIAA0101 tv2 was highly expressed in adjacent non-tumorous liver tissues (NTs) compared to HCC tissues. In vivo and in vitro results showed that KIAA0101 tv2 decreased cell survival, colony formation, tumor xenografts, migration, and invasion, as well as induced cell cycle arrest and apoptosis. Interestingly, it could inhibit the function of KIAA0101 tv1 by partially down-regulating KIAA0101 tv1, acting similar to KIAA0101 tv1 short hairpin RNA (shRNA). Further studies illustrated that KIAA0101 tv2 could increase the activity of p53 by competing with KIAA0101 tv1 for P53 binding. In conclusion, KIAA0101 tv2 exerts anti-tumor activity in HCC and acts as an endogenous competitor of tumor-associated KIAA0101 tv1. KIAA0101 tv2 has a potential to work as a therapeutic drug targeting the KIAA0101 tv1 in HCC.
28410205	0	9	Variant 2	T028	C0678941
28410205	13	21	KIAA0101	T028	C1537443
28410205	40	49	oncogenic	T028	C0029016
28410205	50	59	variant 1	T028	C0678941
28410205	82	102	therapeutic strategy	T061	C0087111
28410205	106	130	hepatocellular carcinoma	T191	C2239176
28410205	131	155	Hepatocellular carcinoma	T191	C2239176
28410205	157	160	HCC	T191	C2239176
28410205	181	187	lethal	T033	C3151529
28410205	188	204	malignant tumors	T191	C0006826
28410205	205	214	worldwide	T098	C2700280
28410205	229	238	therapies	T061	C0087111
28410205	250	267	molecular therapy	T061	C0017296
28410205	276	283	elusive	T080	C0332218
28410205	321	330	oncogenic	T028	C0029016
28410205	331	339	KIAA0101	T028	C1537443
28410205	340	358	transcript variant	T028	C0678941
28410205	359	365	(tv) 1	T028	C0678941
28410205	366	374	promotes	T052	C0033414
28410205	375	378	HCC	T191	C2239176
28410205	379	390	development	T169	C1527148
28410205	406	409	HCC	T191	C2239176
28410205	410	421	therapeutic	T169	C0302350
28410205	422	428	target	T169	C1521840
28410205	443	451	function	T169	C0542341
28410205	463	471	KIAA0101	T028	C1537443
28410205	472	479	variant	T028	C0678941
28410205	481	489	KIAA0101	T028	C1537443
28410205	490	493	tv2	T028	C0678941
28410205	503	510	unknown	T080	C0439673
28410205	544	552	KIAA0101	T028	C1537443
28410205	553	556	tv2	T028	C0678941
28410205	561	567	highly	T080	C0205250
28410205	568	577	expressed	T045	C0017262
28410205	581	589	adjacent	T082	C0205117
28410205	590	616	non-tumorous liver tissues	T023	C0736268
28410205	618	621	NTs	T023	C0736268
28410205	623	631	compared	T052	C1707455
28410205	635	638	HCC	T191	C2239176
28410205	639	646	tissues	T023	C0736268
28410205	648	655	In vivo	T062	C0681829
28410205	660	668	in vitro	T062	C0681828
28410205	669	683	results showed	T033	C0683954
28410205	689	697	KIAA0101	T028	C1537443
28410205	698	701	tv2	T028	C0678941
28410205	702	711	decreased	T081	C0205216
28410205	712	725	cell survival	T043	C0007620
28410205	727	733	colony	T025	C1947989
28410205	734	743	formation	T169	C1522492
28410205	745	761	tumor xenografts	T059	C0917891
28410205	763	772	migration	T043	C1622501
28410205	778	786	invasion	T033	C1269955
28410205	799	806	induced	T169	C0205263
28410205	807	824	cell cycle arrest	T043	C1155873
28410205	829	838	apoptosis	T043	C0162638
28410205	864	871	inhibit	T052	C3463820
28410205	876	884	function	T169	C0542341
28410205	888	896	KIAA0101	T028	C1537443
28410205	897	900	tv1	T028	C0678941
28410205	904	913	partially	T081	C0728938
28410205	914	929	down-regulating	T169	C1260953
28410205	930	938	KIAA0101	T028	C1537443
28410205	939	942	tv1	T028	C0678941
28410205	962	970	KIAA0101	T028	C1537443
28410205	971	974	tv1	T028	C0678941
28410205	975	992	short hairpin RNA	T114	C2930586
28410205	994	999	shRNA	T114	C2930586
28410205	1035	1043	KIAA0101	T028	C1537443
28410205	1044	1047	tv2	T028	C0678941
28410205	1054	1062	increase	T169	C0442805
28410205	1067	1075	activity	T169	C0205177
28410205	1079	1082	p53	T028	C0079419
28410205	1101	1109	KIAA0101	T028	C1537443
28410205	1110	1113	tv1	T028	C0678941
28410205	1118	1129	P53 binding	T044	C1817303
28410205	1146	1154	KIAA0101	T028	C1537443
28410205	1155	1158	tv2	T028	C0678941
28410205	1166	1176	anti-tumor	T080	C2986475
28410205	1177	1185	activity	T169	C0205177
28410205	1189	1192	HCC	T191	C2239176
28410205	1208	1218	endogenous	T169	C0205227
28410205	1233	1258	tumor-associated KIAA0101	T028	C1537443
28410205	1259	1262	tv1	T028	C0678941
28410205	1264	1272	KIAA0101	T028	C1537443
28410205	1273	1276	tv2	T028	C0678941
28410205	1306	1322	therapeutic drug	T121	C1254351
28410205	1323	1332	targeting	T063	C0242613
28410205	1337	1345	KIAA0101	T028	C1537443
28410205	1346	1349	tv1	T028	C0678941
28410205	1353	1356	HCC	T191	C2239176